Pediatricians' views on financial barriers and values for pneumococcal vaccine for children

Ambulatory Pediatrics

Volumn 2, Issue 5, 2002, Pages 358-366

  Lieu, Tracy A ^a   Finkelstein, Jonathan A ^a   Adams, Melissa M ^b   Miroshnik, Irina L ^a   Lett, Susan M ^c   Palfrey, Sean ^d   Freed, Gary L ^e   Kleinman, Ken ^a   Ray, G Thomas ^f   Platt, Richard ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f DIVISION OF RESEARCH   (United States)

Author keywords

Economics; Health policy; Vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; CHILD CARE; CONTROLLED STUDY; DRUG COST; FEMALE; GOVERNMENT; HEALTH CARE FINANCING; HEALTH INSURANCE; HUMAN; MALE; OUTCOMES RESEARCH; PEDIATRICIAN; QUESTIONNAIRE; RANDOMIZATION; REIMBURSEMENT; STATISTICAL MODEL; STREPTOCOCCUS INFECTION; UNITED STATES;

EID: 18644376557     PISSN: 15301567     EISSN: None     Source Type: Journal    
DOI: 10.1367/1539-4409(2002)002<0358:PVOFBA>2.0.CO;2     Document Type: Article

References (29)

1. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academy Press; 2001.
2. Gafni A. Willingness-to-pay as a measure of benefits. Med Care. 1991;29:1246-1252.
3. Zeckhauser R. Procedures for valuing lives. Public Policy. 1975;23:419.
4. Thompson MS, Read JL, Liang M. Willingness-to-pay concepts for societal decisions in health. In: Kane RL, ed. Values and Long-Term Care. Lexington, Mass: Lexington Books; 1982: 103-125.
5. Thompson MS, Read JL, Liang M. Feasibility of willingness-to-pay measurement in chronic arthritis. Med Decis Making. 1984;4:195-215.
6. McCullagh P, Nelder JA. Generalized Linear Models. New York, NY: Chapman and Hall; 1983.
7. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283:1460-1468.
8. Council of American Survey Research Organizations. On the Definition of Response Rates: A Special Report from the CAS-RO Task Force on Completion Rates. Port Jefferson, NY: Council of American Survey Research Organizations; 1982.
9. Freed GL, Bordley WC, Clark SJ. Universal hepatitis B immunization of infants: reactions of pediatricians and family physicians over time. Pediatrics. 1994;93:747-751.
10. Freed GL, Freeman VA, Clark SJ. Pediatrician and family physician agreement with and adoption of universal hepatitis B immunization. J Fam Pract. 1996;42:587-592.
11. Freed GL, Bordley WC, Clark SJ, Konrad TR. Family physician acceptance of universal hepatitis B immunization of infants. J Fam Pract. 1993;36:153-157.
12. Kraus DM, Campbell MM, Marcinak JFM. Evaluation of universal hepatitis B immunization practices of Illinois pediatricians. Arch Pediatr Adolesc Med. 1994;148:936-942.
13. Wood DL, Rosenthal PM, Scarlata D. California pediatricians' knowledge of and response to recommendations for universal infant hepatitis B immunization. Arch Pediatr Adolesc Med. 1995;149:769-774.
14. Newman RD, Taylor JA. Reactions of pediatricians to the recommendation for universal varicella vaccination. Arch Pediatr Adolesc Med. 1998; 152:792-796.
15. Freed GL, Konrad TR, DeFriese GH. Adoption of a new Haemophilus influenzae type B vaccine recommendation. AJDC, 1993;147:124-128.
16. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000;49:1-38.
17. Miller MA, Hinman AR. Cost-benefit and cost-effectiveness analysis of vaccine policy. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia, Pa: WB Saunders Company; 1999: 1074-1088.
18. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
19. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press; 1987.
20. Lieu TA, Black SB, Ray GT, et al. The hidden costs of infant vaccination. Vaccine. 2001;19:33-41.
21. Kuppermann M, Nease RF, Ackerson LM, et al. Parents' preferences for outcomes associated with childhood vaccinations. Pediatr Infect Dis J. 2000;19:129-133.
22. Sorum PC. Measuring patient preferences by willingness to pay to avoid: the case of acute otitis media. Med Decis Making. 1999;19:27-37.
23. O'Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making. 1994;14:289-297.
24. Chestnut LG, Keller LR, Lambert WE, Rowe RD. Measuring heart patients' willingness to pay for changes in angina symptoms. Med Decis Making. 1996;16:65-77.
25. Johannesson M, Weinstein MC. Designing and conducting cost-benefit analyses. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Pa: Lippincott-Raven Publishers; 1996:1085-1092.
26. McNeil BJ, Pauker SG, Sox HC, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982; 306:1259-1262.
27. Redelmeier DA, Tversky A. Discrepancy between medical decisions for individual patients and for groups. N Engl J Med. 1990;322:1162-1164.
28. Tversky A, Kahneman D. Judgement under uncertainty: heuristics and biases. Science. 1974;185:1124-1131.
29. Pathman DE, Konrad TR, Freed GL, et al. The awareness-to-adherence model of the steps to clinical guideline compliance. Med Care. 1996;34:873-889.